Saroglitazar ameliorates alcoholic liver disease and is associated with enhanced ethanol metabolism

Figure 2 Effect of saroglitazar on liver injury markers and plasma triglyceride in therapeutic study design. Mice were treated with saroglitazar or vehicle for 4 weeks during ethanol feeding. Blood samples were collected 9 hours after the ethanol binge to measure plasma alanine aminotransferase, aspartate aminotransferase, and triglyceride levels. A: It shows plasma alanine aminotransferase concentrations; B: It shows plasma aspartate aminotransferase levels; C: It shows plasma triglyceride levels. Data are presented as mean ± SEM (n = 8 for normal control and n = 9 disease control and treatments). Statistical analysis was performed using one-way analysis of variance followed by Dunnett’s multiple comparison test. ^aP < 0.05 vs disease control group. ALT: Alanine aminotransferase; PO: Orally; OD: Once daily; UDCA: Ursodeoxycholic acid; AST: Aspartate aminotransferase; TG: Triglyceride.